A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
MK-3475-689
NCT03765918
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. Nathaniel Bouganim
Caroline Buote
514-934-1934 poste 26215
|
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
RTOG 1305
NCT02135042
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. George Shenouda
Tatiana Carvalho
514-934-1934 poste 43698
|
A Randomized Study of Vocal-cord Only vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
VOCAL
NCT03759431
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
Diane Trudel
514-890-8000 poste 11181
|
Stereotactic Boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer Trial: A Randomized Multicentric Phase II Trial
SHORT-OPC
NCT04178174
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
Mom Phat
514-890-8000 poste 11171
|
Preservation of Swallowing in Resected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects: A Randomized Trial
PRESERVE
NCT03997643
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
|
Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial
ART-OPC
NCT04901234
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
Silvine Benth
514-890-8000
|
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Head and Neck Cancer: A Phase II Randomized Trial
Suppress-HNC
NCT04989725
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
Mom Phat
514-890-8000 poste 11171
|
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin
XRAY VISION (MS202359-0002)
NCT05386550
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Denis Soulières
Chantal Gosselin
514-890-8000 poste 24892
|
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial
HN11 (SELECT)
NCT05451004
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Head and Neck |
Dr. Isabelle Gauthier
Patricia Roy
819-346-1110 poste 14082
|
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor
INTERLINK-1
NCT04590963
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Head and Neck |
Dr. Khashayar Esfahani
Alessandra Figueiredo De Vasconcelos
514-340-8222 poste 26823
|
Groupe d'étude en oncologie du Québec